The FDA approved oral sulopenem etzadroxil and probenecid (Orlynvah) to treat uncomplicated urinary tract infections (uUTIs) ...

FDA approved Orlynvah for the Tx of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.

However, a 2019 study of over 300 women observed no difference between uva ursi and placebo when they were used as a treatment for active UTIs. Available research suggests uva ursi is relatively ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

Treatment MarketThe global urinary tract infection (UTI) treatment market is poised for consistent growth, with an estimated ...

The US Food and Drug Administration has approved a new oral antibiotic for treatment of uncomplicated urinary tract ...

Oct. 28, 2024 –The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

A group of experts who reviewed evidence on urinary tract infections (UTIs) failed to come up with many recommendations due ...

Nonantibiotic prophylactic options for UTIs such as methenamine hippurate remain significantly underutilized, especially for ...

Roughly 50% of women will experience at least one UTI ... While antibiotics are the go-to treatment for UTIs, the rise of antibiotic resistance and the fact many people experience frequent ...

The treatment has been shown to be active against third generation cephalosporin-resistant Enterobacterales species. Orlynvah combines sulopenem etzadroxil, a penem antibacterial drug, and ...